This is the case for PIK3CA gene mutations in breast cancer, several genomic targets in lung cancer, including in EGFR, ALK, ROS-1, BRAF, MET, RET, KRAS, and NTRK, and BRCA1/2 alterations in prostate cancer. This evidence concerns the gene ROS1 and lung carcinoma.